Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
7,253 total articles
Nano Labs (NA) trades at a $59M market cap with a P/E of 2.84 and PB under 0.6 while sitting on strategic crypto reserves and new AI/edge hardware initiatives. The market has punished the name aggressively; we present a long trade for disciplined investors with an entry at $2.50, stop at $2.10 and a $4.50 target over a 180 trading-day horizon.
SAP's shares have retraced sharply from a $313 52-week high to the $190 area, but underlying momentum, a string of strategic AI and cloud moves, and rising short interest create a setup for a mid-term rebound. This trade idea lays out a concrete long entry at $191.00, a stop at $176.00 and a target at $240.00 over a mid-term (45 trading days) horiz…
Reckitt Benckiser (RBGPF) has tumbled roughly 30% from recent levels. Technical indicators are oversold and short-interest dynamics point to ongoing covering. We upgrade to a Buy on a mid-term swing basis with an entry at $60.01, a stop at $52.00 and a target of $75.00 over ~45 trading days.
Newmont is a high-quality, well-capitalized gold producer trading at a mid-teens P/E and single-digit EV/EBITDA amid elevated gold prices and renewed asset repricing. We present a staged long trade with concrete entry, stop and target levels across short, mid and long horizons.
Vistance Networks (VISN) is sitting on a compact, cash-rich balance sheet after the CCS divestiture and a material special distribution. The market currently prices the remaining business at EV/FCF ~1.3x and EV/EBITDA ~0.37x. If Aurora/Ruckus-like assets deserve anything near the 12-13x multiple paid by strategic buyers, VISN has meaningful upside.…
Capricor Therapeutics is a clinical-stage cell and exosome developer that has both a recent history of regulatory setbacks and a string of positive clinical/regulatory interactions. With a market cap of roughly $1.58B, a cash runway that looks meaningful on a go-forward basis, and elevated short interest, the stock is a high-volatility but asymmetr…
Advanced Micro Devices has moved from momentum trade to a fundamentally defensible buy. Strong AI-driven demand, improving technicals, large free cash flow, and a rock-solid balance sheet underpin a swing trade. Valuation is rich, so risk management is central: entry at $520, stop at $480, target $620 over the next 45 trading days.
Enterprise Products Partners (EPD) presents a compelling buy-the-pullback opportunity. The partnership trades at a modest P/E of ~13.8, yields ~5.9%, generates roughly $2.2B in free cash flow and sits on an $81.5B market cap. With pipeline “toll” economics and growing demand pressure on energy and petrochemical feedstocks from expanding AI datacent…
Microsoft's mix of recurring enterprise software, a dominant cloud franchise, and expanding AI platform products gives it outsized recession resilience. At roughly $3.28 trillion market cap, the stock still offers durable free cash flow, low leverage, and technical momentum. This trade idea lays out an entry, stop, and target for a long bias over a…
Salesforce has the balance sheet, cash flow and AI investments that should drive a bookings rebound in H2. Technical momentum and heavy short interest amplify upside in the near-to-mid term. We lay out a position trade with entry, stop and target and a timeline tied to H2 bookings cadence.
Innovative Solutions & Support (ISSC) doubled revenue in a recent quarter after acquiring Honeywell's F-16 product line. The market is focused on integration pain and a short-term pull-forward; we view this as an opportunity. With a $307M market cap, positive free cash flow and improving technicals, ISSC is a tactical long for a mid-term swing as M…
Rhythm (RYTM) is a commercial-stage rare-disease biotech with an FDA-approved MC4R agonist, IMCIVREE. Recent approvals and a busy June conference/data calendar make the stock a tactical long over the next 45 trading days. Valuation is rich, but near-term catalysts and improving commercial execution justify a mid-term swing trade with defined risk c…
Sterling Infrastructure sits squarely in the AI/data-center supply chain after a rapid re-rating. Strong top-line momentum, a $5.15B backlog and raised guidance argue for continued upside, but the stock trades at a steep multiple. This trade idea targets a mid-term swing entry on a controlled pullback with clear stop and target levels.
Applied Optoelectronics (AAOI) is benefiting from hyperscaler demand for 800G and 1.6T optical modules. Strong tape of volume, improving technicals and continued product-led scarcity support a tactical long. The valuation is rich, so keep position sizing prudent and use a clearly defined stop.
Nebius Group (NBIS) is trading after an all-time high on heavyweight endorsements and multibillion customer commitments. The company is executing an aggressive capacity build to capture AI cloud demand, and recent top-line momentum is explosive. This trade idea outlines a long-biased plan with entry, stop and target that balances the structural gro…
Western Digital has crossed a profitability inflection with 50%+ gross margins and strong free cash flow. The stock is expensive by traditional multiples but momentum and long-term contracts with cloud customers leave room for upside. This is a tactical long trade for swing traders who want exposure to the AI-driven storage narrative while managing…
Nano Labs (NA) trades at roughly $59M market cap, a trailing P/E of ~2.8 and PB ~0.58. The company designs high-performance chips and distributed computing solutions; management has pivoted capital into crypto reserves while cutting operating expenses. Recent CEO purchases, a North America AI data center MOU and new hardware launches create near-te…
Vistra is a cash-generative independent power producer with large-scale generation, growing exposure to data-center and AI load through long-term contracts, and an improving valuation lens versus idiosyncratic 2026 sell-offs. Strong free cash flow, a sizeable market cap, and recent corporate actions make a buy-with-a-plan trade attractive for patie…
CoreWeave is trading materially below its 52-week high after a volatile stretch. With revenue growth well into triple digits, a $99.4B backlog, and an enlarged Nvidia stake validating its strategic position in AI infrastructure, CoreWeave looks like a compelling core long for investors willing to accept elevated balance-sheet and concentration risk…
Celestica (CLS) has sharply re-rated as its Advanced Technology and Connectivity segments scale into AI, cloud networking and aerospace. Recent results showed 53% revenue growth and raised FY26 guidance to $19.0B and $10.15 adjusted EPS. Momentum is strong, but valuation is rich. This trade idea buys a measured pullback for a long-term (180 trading…
Willis Towers Watson (WTW) sold off after Q1 margin weakness and tepid organic growth, but the pullback looks overdone. At $256.41, WTW trades at ~15x EPS with $1.57B in free cash flow and a manageable debt load. This trade idea targets a rebound to $320 over the next 180 trading days, using a logical stop at the recent 52-week low to protect downs…
Carvana just saw used-car pricing pressure flip into a tailwind. With headline used-car prices at a two-year high, improving margins, strong free cash flow, and a crowded short book, CVNA offers an asymmetric risk-reward for disciplined longs. Trade plan below targets a move back toward the post-split highs while respecting the company’s elevated v…
MannKind (MNKD) just cleared a major commercial milestone with FDA approval of Afrezza for children and adolescents 6 and older. Q1 2026 revenue momentum (15% YoY to $90.2M) and multiple upcoming presentations create a near-term re-rating opportunity. This trade idea lays out an entry, stop, and target with a clear horizon and risk framework tied t…
Surge Energy is a levered play on a sustained oil-price recovery. Operational leverage, tight cost structure, and disciplined capital allocation make this an actionable long with a clear risk-managed entry at $2.40, stop at $1.80 and primary target at $4.00 over the next 180 trading days.
Madrigal Pharmaceuticals (MDGL) is a commercial-stage liver-focused biotech with an FDA- and EC-approved therapy (Rezdiffra) and a growing combination-ready pipeline. The balance sheet, recent licensing deals and an oversold technical setup create an asymmetric trade: entry at $452.76, stop at $360.00, target $800.00 over a long-term window (180 tr…
